Literature DB >> 8110440

SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain.

T Brücke1, J Kornhuber, P Angelberger, S Asenbaum, H Frassine, I Podreka.   

Abstract

Single photon emission computerized tomography (SPECT) studies in non-human primates have previously shown that the cocaine derivative [123I]-2-beta-carbomethoxy-3-beta-(4-iodophenyl)-tropane ([123I]beta-CIT) labels dopamine transporters in the striatum and serotonin transporters in the hypothalamus-midbrain area. Here, we report on the regional kinetic uptake of [123I]beta-CIT in the brain of 4 normal volunteers and 2 patients with Parkinson's disease. In healthy subjects striatal activity increased slowly to reach peak values at about 20 hours post injection. In the hypothalamus-midbrain area peak activities were observed at about 4 hours with a slow decrease thereafter. Low activity was observed in cortical and cerebellar areas. The striatal to cerebellar ratio was about 4 after 5 hours and 9 after 20 hours. In 2 patients with idiopathic Parkinson's disease striatal activity was markedly decreased while the activity in hypothalamus-midbrain areas was only mildly diminished. Uptake into cortical and cerebellar areas appeared to be unchanged in Parkinson's disease. Consequently, in Parkinson's disease the striatal to cerebellar ratio was decreased to values around 2.5 after 20 hours. These preliminary methodological studies suggest that [123I]beta-CIT is a useful SPECT ligand for studying dopamine and possibly also serotonin transporters in the living human brain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8110440     DOI: 10.1007/bf01245007

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  17 in total

1.  Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease.

Authors:  P Allard; I Alafuzoff; A Carlsson; K Eriksson; E Ericson; C G Gottfries; J O Marcusson
Journal:  Eur Neurol       Date:  1990       Impact factor: 1.710

2.  [125I]RTI-55: a potent ligand for dopamine transporters.

Authors:  J W Boja; A Patel; F I Carroll; M A Rahman; A Philip; A H Lewin; T A Kopajtic; M J Kuhar
Journal:  Eur J Pharmacol       Date:  1991-02-26       Impact factor: 4.432

3.  In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55.

Authors:  E K Shaya; U Scheffel; R F Dannals; G A Ricaurte; F I Carroll; H N Wagner; M J Kuhar; D F Wong
Journal:  Synapse       Date:  1992-02       Impact factor: 2.562

4.  Decreased density of human striatal dopamine uptake sites with age.

Authors:  N Zelnik; I Angel; S M Paul; J E Kleinman
Journal:  Eur J Pharmacol       Date:  1986-07-15       Impact factor: 4.432

5.  SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates.

Authors:  M Laruelle; R M Baldwin; R T Malison; Y Zea-Ponce; S S Zoghbi; M S al-Tikriti; E H Sybirska; R C Zimmermann; G Wisniewski; J L Neumeyer
Journal:  Synapse       Date:  1993-04       Impact factor: 2.562

6.  [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane: high-affinity SPECT radiotracer of monoamine reuptake sites in brain.

Authors:  J L Neumeyer; S Y Wang; R A Milius; R M Baldwin; Y Zea-Ponce; P B Hoffer; E Sybirska; M al-Tikriti; D S Charney; R T Malison
Journal:  J Med Chem       Date:  1991-10       Impact factor: 7.446

7.  [123/125I]RTI-55, an in vivo label for the serotonin transporter.

Authors:  U Scheffel; R F Dannals; E J Cline; G A Ricaurte; F I Carroll; P Abraham; A H Lewin; M J Kuhar
Journal:  Synapse       Date:  1992-06       Impact factor: 2.562

8.  The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus.

Authors:  H B Niznik; E F Fogel; F F Fassos; P Seeman
Journal:  J Neurochem       Date:  1991-01       Impact factor: 5.372

9.  Decreased imipramine binding in the brains of patients with depressive illness.

Authors:  E K Perry; E F Marshall; G Blessed; B E Tomlinson; R H Perry
Journal:  Br J Psychiatry       Date:  1983-02       Impact factor: 9.319

Review 10.  MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease.

Authors:  M Gerlach; P Riederer; H Przuntek; M B Youdim
Journal:  Eur J Pharmacol       Date:  1991-12-12       Impact factor: 4.432

View more
  25 in total

1.  SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain.

Authors:  J Kornhuber; T Brücke; P Angelberger; S Asenbaum; I Podreka
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom.

Authors:  Walter Koch; Perry E Radau; Wolfgang Münzing; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-25       Impact factor: 9.236

3.  Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study.

Authors:  V Caretti; D Stoffers; A Winogrodzka; I-U Isaias; G Costantino; G Pezzoli; C Ferrarese; A Antonini; E-Ch Wolters; J Booij
Journal:  J Neural Transm (Vienna)       Date:  2008-03-12       Impact factor: 3.575

4.  [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.

Authors:  J Booij; G Tissingh; G J Boer; J D Speelman; J C Stoof; A G Janssen; E C Wolters; E A van Royen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

Review 5.  The role of neurotransporters in excitotoxicity, neuronal cell death, and other neurodegenerative processes.

Authors:  K P Lesch; A Heils; P Riederer
Journal:  J Mol Med (Berl)       Date:  1996-07       Impact factor: 4.599

6.  Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment.

Authors:  K Weissenborn; J C Ennen; M Bokemeyer; B Ahl; U Wurster; H Tillmann; C Trebst; H Hecker; G Berding
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

Review 7.  Early detection of Parkinson's disease. Implications for treatment.

Authors:  R Di Paola; R J Uitti
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

Review 8.  Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data.

Authors:  B Scholtissen; F R J Verhey; H W M Steinbusch; A F G Leentjens
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

9.  [123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials.

Authors:  Oliver Pogarell; Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

10.  Comparison of [123I]beta-CIT and [123I]IPCIT as single-photon emission tomography radiotracers for the dopamine transporter in nonhuman primates.

Authors:  B E Scanley; M S al-Tikriti; M S Gandelman; M Laruelle; Y Zea-Ponce; R M Baldwin; S S Zoghbi; P B Hoffer; D S Charney; S Wang
Journal:  Eur J Nucl Med       Date:  1995-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.